Fintel reports that Armistice Capital has filed a 13G form with the SEC disclosing ownership of 1.03MM shares of Cyclo Therapeutics Inc (CYTH). This represents 10.8% of the company.
In their previous filing dated December 11, 2020 they reported 0.22MM shares and 4.99% of the company, an increase in shares of 378.34% and an increase in total ownership of 5.81% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 222.78% Upside
As of February 10, 2023, the average one-year price target for Cyclo Therapeutics is $5.10. The forecasts range from a low of $5.05 to a high of $5.25. The average price target represents an increase of 222.78% from its latest reported closing price of $1.58.
The projected annual revenue for Cyclo Therapeutics is $3MM, an increase of 64.09%. The projected annual EPS is -$1.00.
What is the Fund Sentiment?
There are 23 funds or institutions reporting positions in Cyclo Therapeutics. This is a decrease of 1 owner(s) or 4.17% in the last quarter. Average portfolio weight of all funds dedicated to CYTH is 0.00%, a decrease of 89.79%. Total shares owned by institutions decreased in the last three months by 0.73% to 456K shares.
What are large shareholders doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 177K shares representing 1.80% ownership of the company. No change in the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 71K shares representing 0.72% ownership of the company. No change in the last quarter.
Renaissance Technologies holds 48K shares representing 0.49% ownership of the company. In it's prior filing, the firm reported owning 64K shares, representing a decrease of 31.95%. The firm decreased its portfolio allocation in CYTH by 10.85% over the last quarter.
Geode Capital Management holds 48K shares representing 0.49% ownership of the company. No change in the last quarter.
FSMAX - Fidelity Extended Market Index Fund holds 28K shares representing 0.29% ownership of the company. In it's prior filing, the firm reported owning 28K shares, representing a decrease of 0.16%. The firm decreased its portfolio allocation in CYTH by 28.21% over the last quarter.
Cyclo Therapeutics Background Information
(This description is provided by the company.)
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
